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study and algorithmic approach
Benjamin Thomas1,2* , Maria Benedikt1,3, Ali Alamri1, Florian Kapp1, Rainer Bader4, Burkhard Summer1,
Peter Thomas1 and Eva Oppel1
Abstract: Background: Antibiotic-loaded (particularly gentamicin) bone cement (BC) is widely used in total joint
arthroplasty (TJA) to prevent periprosthetic infections (PPIs), but may itself cause implant failure. In light of a
complete lack in literature, the objective was to assess the clinical relevance of gentamicin allergy for failure of
cemented total knee arthroplasties in 25 out of 250 patients with positive patch test reactions to gentamicin and
otherwise unexplained symptoms by evaluating benefits from revision with change to gentamicin-free cement.
Methods: Fifteen of these 25 patients and their treating orthopaedic surgeons agreed to a re-assessment. They
were surveyed regarding interim course of therapy and symptoms, including re-assessment of the Knee Injury and
Osteoarthritis Outcome Score (KOOS), and underwent follow-up clinical and radiographic investigations. The initial
use of gentamicin-loaded BC was reaffirmed by review of the primary implantation operative reports and respective
implant passports. Primary and follow-up KOOS scores were analyzed regarding benefits from revision surgery by
comparing nine patients with revision to six without revision.
Results: Mean follow-up time was 38 months. The entirety of patients experienced an improvement of self-
reported symptoms, with revision surgery (i.e., switching to gentamicin-free BC or uncemented total knee
arthroplasty) yielding significantly greater improvement (p = 0.031): the nine revised patients reported a significant
symptom relief (p = 0.028), contrary to the six unrevised patients (p = 0.14). Interestingly, the decision to proceed
with revision surgery was significantly correlated with higher symptom severity (p = 0.05).
Conclusion: In symptomatic total knee arthroplasty with gentamicin allergy, uncemented revision arthroplasty or
change to gentamicin-free BC provides significant symptom relief.
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Background
Total joint replacement (TJR) is efficient and successful in
the treatment of degenerative and inflammatory joint
disorders: TJR can restore joint function, alleviate pain, and
help regain quality of life. Therefore, total hip (THR) and
knee replacement (TKR) have been acknowledged as the
gold standard in advanced symptomatic osteoarthritis of the
hip and knee joint. Today, approximately one million TJRs
are implanted in the USA per year, with numbers projected
to quadruple within the next two decades [1, 2]. However,
there is a serious, yet frequent drawback to this success
story: 9% of all TJR surgeries are complication-related revi-
sions [3]. With an annual incidence of 1 to 3%, peripros-
thetic infection (PPI) brings about particularly poor clinical
outcomes and technically difficult revision surgery [4, 5].
Moreover, the treatment costs of PPIs increase fourfold
compared to primary implantations [6]. Alarmingly, the
annual economic burden of infectious joint revisions is
projected to exceed $1.5 billion by the end of 2019 [7].
Understandably, many attempts have been undertaken to
reduce the incidence of PPIs, such as administering systemic
antibiotics, or the use of antibiotic-loaded bone cement
(ALBC).
Nowadays, poly-methylmethacrylate (PMMA)-based
bone cement (BC) is the most widely used antibiotic
vehicle in this context. This BC comprises a two-part
system composed of a powdery and a liquid component.
The former contains an acrylic MMA-polymer and an
initiator (e.g., benzyl peroxide [BPO]) to start the redox
polymerization, and the latter contains an acrylic MMA-
monomer, an activator to maintain the polymerization
reaction (e.g., N,N-dimethyl-p-toluidine [DMPT]), and a
stabilizer to prevent premature curing (e.g., hydroquin-
one) [8, 9]. Based on the premise of enhanced prostheses
fixation and prophylactic antibiotic delivery, standard
use of ALBC has been common practice in the UK [10, 11],
Scandinavia [12], and Germany [13]. On the contrary,
despite representative polls reporting an increasing use of
primary prophylactic ALBC [14], the majority of ortho-
paedic surgeons in the USA remain skeptical [15].
Regarding the assumption of increased arthroplasty
fixation, the literature is inconclusive for cementing joint
replacements. On the one hand, cemented THRs exhibit
superior long-term as well as short-term survival [16].
On the other hand, however, whether cemented TKRs
yield superior overall survivorship remains uncertain
[16]. Likewise, the antimicrobial efficacy of ALBC has
not been convincingly demonstrated. Despite strong
evidence of high local antibiotic concentrations, both
immediately after implantation and sustainably over
several months [17–19], its clinical benefit remains
controversial: while some meta-analyses report a signifi-
cantly reduced PPI rate in primary and revision arthroplasty
[20, 21], others found no effect [22, 23]. This discrepancy is
further aggravated by several key disadvantages, such as the
development of antibiotic-resistant bacterial strains [24,
25], thermal injury to surrounding tissues [26, 27], econom-
ical expenses for hospitals and tax payers [28], and the risk
of allergenic potential to surgeons and patients [29–31].
We recently reported on 250 patients who had been
referred to our outpatient allergy clinic with a history of
complicated cemented arthroplasty and suspected implant
allergy [32]. After mechanical problem elicitors, such as
loosening or malalignment, had been ruled out by the
transferring orthopaedic surgeon by means of clinical and
radiographic investigations, extended patch testing with
implant metals and the additional BC series was carried
out at our clinic. We found positive reactions in 138
patients (55%), in particular, 41/138 reactions (30%) to
implant metals and 49/138 (36%) to BC components.
Interestingly, gentamicin sulfate triggered positive readouts
in 25/250 patients (10%), with 17/25 reactions (68%) only
appearing as late as day 6. However, the clinical relevance
of positive patch tests to BC components has merely been
suggested in a handful of case reports [33–36], with litera-
ture on revisions in the context of gentamicin allergy lack-
ing completely. Thus, we followed up with our patients in
an effort to investigate the rate and outcomes of re-
operations in this cohort. To this end, our present study is
the first to objectify symptom improvement after TJR and
ALBC exchange in the context of gentamicin allergy. Our
data emphasize both the clinical importance of an
adequate work-up in cases of suspected allergic implant




The present retrospective case series was approved by
the local ethics committee (Reference number 159-14).
By way of background, for over 20 years, we have been
offering outpatient consultations for patients suspected
of suffering from adverse implant reactions. Presenting
with otherwise unexplained complicated and painful
TJRs, dental and osteosynthetic materials, or other im-
plants, such as cardiac pacers, these patients are referred
to us by colleagues from a wide variety of fields. Accord-
ing to general consensus, we request that commonplace
symptom elicitors be eliminated antecedently. In line
with this, extrinsic factors are ruled out, and diagnostic
approaches to potential articular etiologies are exhausted
prior to consulting with us (Fig. 1). Once symptomatic
patients have completed this initial orthopaedic routine
work-up with inconclusive results, other systemic symptom
elicitors are ruled out before specific allergic testing is
commenced (Fig. 2). In order to establish the diagnosis of
exclusion of an adverse implant reaction, a three-stage
work-up algorithm is then followed: (1) Patch testing is
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initiated with three sets of substances (common allergens,
metallic allergens, and bone cement components, see
Tables 1 and 2). This is accompanied by lymphocyte trans-
formation testing in order to check for acquired systematic
sensitization as well as histopathological assessment of
potential locoregional periprosthetic hypersensitivity.
Amongst the previously tested 250 patients, all TKR
bearers with positive patch test reactions to gentamicin
were invited to a follow-up appointment at our clinic, as
well as clinical and radiographic investigations carried out
by the treating orthopaedic surgeons. Initial questionnaire-
aided history, self-reported and questionnaire-aided anam-
nesis (including the German version of the Knee Injury and
Osteoarthritis Outcome Score [KOOS]) [37, 38], and results
from examinations for atopic diathesis were readily avail-
able, in addition to the primary clinical and radiographic
orthopaedic examinations. An extended European baseline
patch test series (Almirall Hermal, Reinbek, Germany),
extended metal series (Chemotechnique Diagnostics,
Vellinge, Sweden), and BC series had been tested as
Fig. 1 Traditional orthopaedic work-up of common problem elicitors. The initial work-up for complicated TKAs is carried out by the treating
orthopaedic surgeon and commences with detailed history taking and a through clinical examination. Once systemic and extra-articular
etiologies are ruled out, specific TKA-related problems are addressed. In cases of inconclusive work-up, rare conditions, such as allergic or adverse
reactions, should be considered as diagnoses of exclusion (R/O, rule out; CT, computed tomography; CRP, C-reactive protein; WBC, white blood
cell count; ESR, erythrocyte sedimentation rate; PCT, procalcitonin; IL-6 , interleukin-6, SPECT, single photon emission computed tomography; PET,
positron emission tomography; MRI, magnetic resonance imaging)
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previously described [32], and readouts had likewise been
documented in our database. Primary TKR fixation with
gentamicin-loaded BC was reaffirmed by review of the
respective operative reports and implant passports.
Figure 3 illustrates the underlying patient inclusion/ex-
clusion criteria for the present follow-up study.
Follow-up procedure
After obtaining written informed consent, patients were
reexamined by the referring orthopaedic surgeon and then
re-assessed at our clinic by (i) means of a set of follow-up
questions including potential revision surgeries with ex-
change of implant or BC components, (ii) recording any
history of past and present implant-related complaints and
the course of symptoms, and (iii) re-assessment of the
KOOS Index. Based on the reported incidence of revision,
patients were grouped into an “untreated’”(i.e., no revision
with exchange of implant or BC components) and a
“treated” cohort (i.e., revision with change to an uncemen-
ted TKA or re-implantation with gentamicin-free cement).
Fig. 2 Algorithmic interdisciplinary approach to complicated TKAs with suspected allergic or adverse reactions. Following an inconclusive work-
up for commonplace problem elicitors, symptomatic TKA-bearers should be sent for patch testing, particularly in cases of atopic diathesis or
positive family history of allergy. After ruling out other systemic disorders, epicutaneous testing for relevant metal implant or bone cement
hypersensitivities is carried out. This is typically accompanied by lymphocyte transformation testing for systemic sensitization and, in cases of
earlier revisions or arthroscopic debridements, histopathological assessment (R/O, rule out; BPO, benzyl peroxide; MMA, methylmethacrylate;
DMPT, N,N-dimethyl-p-toluidine; HQ, hydroquinone)
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Statistics
Statistical analysis was performed with IBM SPSS Version
20 (IBM Corporation, Armonk, NY, USA) and Graphpad
Prism Version 7 (Graphpad Software, Inc., La Jolla, CA,
USA). Primary and follow-up KOOS scores were compared
using the paired t test to assess the differences in means.
To assess the relationship between baseline KOOS scoring
and the grouping variable (“treated” versus “untreated”), a
one-tailed Pearson correlation coefficient was computed
using a linear bivariate regression model. A two-way
repeated-measures analysis of variance (ANOVA) was then
run to determine whether the independent grouping vari-
able (“treated” versus “untreated”) had an effect on KOOS




Twenty-five symptomatic TKR bearers with proven
gentamicin hypersensitivity were identified and invited
to a follow-up interview, as well as clinical and radio-
graphic investigations, with 15 of 25 allergic patients
(60%) agreeing to partake in our study. The entire
follow-up cohort of these 15 gentamicin allergic patients
had initially been treated with cemented TKRs based on
cobalt, chromium, and molybdenum (CoCrMo) alloy,
which typically include ∼ 65% cobalt, ∼ 28% chromium,
∼ 6% molybdenum, and up to 1% nickel. The median
age was 66 years (49–74 years), and 8 (53%) patients
were female. All 15 patients had initially been referred to
our clinic because of persistent and otherwise unexplained
Table 1 As part of the European baseline series (EBS) of haptens (contact allergens), 29 substances, prepared at different
concentrations (conc.) in either a petrolatum (pet.) or aqueous (aq.) base (veh. = vehicle), are applied to the patient’s upper back in
the form of a standardized commercially available patch test set
European baseline series Allergen Conc. Veh. Readings
Potassium dichromate 0.5% pet. D2, D3, D6
Thiuram mix 1.0% pet. D2, D3, D6
Cobalt(II) chloride 1.0% pet. D2, D3, D6
Myroxylon pereirae 25% pet. D2, D3, D6
Colophonium 20% pet. D2, D3, D6
N-isopropyl-N′ -phenyl-p-phenylenediamine 0.1% pet. D2, D3, D6
Lanolin alcohol 30% pet. D2, D3, D6
Mercapto mix 1.0% pet. D2, D3, D6
Epoxy resin 1.0% pet. D2, D3, D6
Nickel(II) sulfate 5.0% pet. D2, D3, D6
p-tert-Butylphenol formaldehyde resin 1.0% pet. D2, D3, D6
Formaldehyde 1.0% aq. D2, D3, D6
Fragrance mix I 8.0% pet. D2, D3, D6
Turpentine 10% pet. D2, D3, D6
Methylchloroisothiazolinone/methylisothiazolinone 100 ppm aq. D2, D3, D6
Paraben mix 16% pet. D2, D3, D6
Cetearyl alcohol 20% pet. D2, D3, D6
Zinc diethyldithiocarbamate 1.0% pet. D2, D3, D6
Methyldibromo glutaronitrile 0.2% pet. D2, D3, D6
Propolis 10% pet. D2, D3, D6
Bufexamac 5.0% pet. D2, D3, D6
Compositae mix II 5.0% pet. D2, D3, D6
Mercaptobenzothiazole 2.0% pet. D2, D3, D6
Hydroxyisohexyl 3-cyclohexene carboxaldehyde 5.0% pet. D2, D3, D6
2-Bromo-2-nitropropane-1,3-diol 0.5% pet. D2, D3, D6
Fragrance mix II 14% pet. D2, D3, D6
Ylang Ylang (I + II) oil 10% pet. D2, D3, D6
Sandalwood oil 10% pet. D2, D3, D6
Jasmine absolute 5.0% pet. D2, D3, D6
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Table 2 As part of the extended metal and bone cement series, 11 additional substances, each commercially available and
prepared at different concentrations (conc.) in either a petrolatum (pet.) or aqueous (aq.) base (veh. = vehicle), are applied to the
patient’s upper back in an individualized test set
Metal and bone cement series Allergen Conc. Veh. Readings
Titanium(IV)-oxide 0.1% pet. D2, D3, D6
Manganese(II)-chloride 0.5% pet. D2, D3, D6
Molybdenum(V)-chloride 2.0% pet. D2, D3, D6
Vanadium-pentoxide 10% pet. D2, D3, D6
2-Hydroxyethylmethacrylate 1.0% pet. D2, D3, D6
Copper(II) sulfate 1.0% aq. D2, D3, D6
Benzoyl peroxide 1.0% pet. D2, D3, D6
Gentamicin sulfate 20% pet. D2, D3, D6
Hydroquinone 1.0% pet. D2, D3, D6
N,N-Dimethyl-p-toluidine 2.0% pet. D2, D3, D6
Methylmethacrylate 2.0% pet. D2, D3, D6
Fig. 3 Flowchart of patient inclusion and exclusion criteria
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symptoms related to their TKR, after commonplace failure
modes, such as bacterial infection, aseptic loosening, or
malalignment had been excluded by the transferring
orthopaedic surgeon prior to consultation with us. The
mean implant to allergy work-up interval amounted to 18
months (4–53months). At first visit, 12 patients com-
plained of joint pain and limited mobility, respectively, 11
reported a history of recurrent swellings, and 7 noted
intermittent joint effusions. Eczema (n = 3) and erythema
(n = 1) were seldom stated (multiple complaints were re-
ported per individual patient). Four patients had noticed
previous adverse reactions (e.g., pruritus, erythema, and
eczema) upon contact with metallic objects, such as wrist-
watches or jewelry. Furthermore, 6 patients reported a
family history of atopic diathesis. None recalled “intoler-
ance” reactions to topical drugs (including potential
gentamicin-containing ointments, such as ear or eye
drops). All patients had been found to be patch test posi-
tive—i.e., allergic—to gentamicin, with one patient react-
ing to both gentamicin and BPO. Moreover, two patients
had combined reactions to gentamicin sulfate and nickel
(II) sulfate. As part of our follow-study, re-assessment in-
cluding repeated KOOS scoring was carried out after a
mean follow-up period of 38months (23–56months).
Figure 4 illustrates the chronological sequence of the
aforementioned time intervals. In addition, a detailed
summary of patient characteristics is given in Table 3.
Decision to proceed with revision surgery
Overall, there was a significant difference between pri-
mary and follow-up KOOS scores for the entirety of all
15 patients (t = 3.258, p = 0.006, n = 15, 95% CI 7.124,
34.53), namely, less severe symptoms were reported at
the time of our follow-up interview (M = 62.59, SD =
14.42) compared to the primary scoring (M = 41.73, SD
= 20.19). A total of 9 patients had undergone revision
surgeries with both the exchange of the TKR and re-
moval of the gentamicin-loaded BC, corresponding to a
“treatment” rate of 60%. Mean implant durability before
revision was 22months (15–38 months). Revision sur-
gery was carried out after a mean interval of 4 months
(2–7 months) following our diagnosis of gentamicin con-
tact allergy. For all revisions, change to an uncemented
TKA or re-implantation with gentamicin-free cement
was confirmed by the operative report and implant
passport. There was a significant negative correlation be-
tween baseline KOOS scores and the decision to proceed
with surgery (r = − 0.442, n = 15, p = 0.050). By way of
explanation, high degree of symptom severity (reflected
by low KOOS scores) led to an increased probability of
revision surgery. A scatterplot visualizes this relationship
(Fig. 5). No unequivocal pathologic clinical (i.e., limited
range of motion) or radiographic (i.e., malalignment or
loosening) findings prompted any of the revision surger-
ies. In fact, our work-up results were indicated as the
decisive criterion in favor of re-operation in all cases.
Beneficial effect of gentamicin-free revision
Since we were not only interested in the motivation to
proceed with revision, but also in the efficacy of these
procedures, a repeated measures factorial ANOVA with
“treatment status” as an independent binary factor and
KOOS scoring as a repeated within-subjects factor was
run. This analysis demonstrated a significant effect of
the grouping variable (“treated” versus “untreated”) in
the assumed direction (F(1, 13) = 5.877, p = 0.031), with
significantly higher symptom relief after revision surgery
(Figure 6). Further subgroup analysis using the paired t-
test confirmed this significant improvement in the ‘treat-
ment’ group (t = 2.627, p = 0.028, n = 9, 95% CI: 3.289,
44.73). In contrast, there was no significant change in
KOOS scores for patients without revision (t = 1.748, p
= 0.14, n = 6, 95% CI: -7.555, 39.65). Remarkably, one
patient of the revision group, however, displayed a score
deterioration of 14.4 points (highlighted in dark red in
Fig. 6). Upon further investigation, the patient’s treating
orthopaedic surgeon disclosed his diagnosis of severe
intra-articular arthrofibrosis. This multi-faceted compli-
cation of TKR is characterized by excessive scar forma-
tion, low responsiveness to surgery, and poor functional
and symptomatic outcomes [39].
Fig. 4 Timeline of patient recruitment and follow-up
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Discussion
Our follow-up investigation revealed that severely
impaired TKA patients were more likely to not only
acknowledge previously detected gentamicin allergy,
but also to undergo revision surgery. Postoperative
re-evaluation showed a significant improvement in
KOOS scores in these patients—i.e., they benefited
greatly from revision surgery. Since none of the trad-
itional symptom elicitors had previously been detected
(such as PPI or malalignment), allergy work-up was
not only simply requested, but proven gentamicin al-
lergy was in fact regarded as indication for revision
surgery by the treating surgeons. This underlines the
importance of a thorough allergy work-up in cases of
otherwise unexplained TJR symptoms.
Indeed, up to 20% of TKA bearers remain dissatisfied
and complain of persisting symptoms, such as joint stiff-
ness, loss of range of motion, knee pain, and recurrent
swelling or edema, following TKR [40, 41]. Despite a cer-
tain disagreement regarding the definition of arthroplasty
failure in this context, almost a quarter of all TKA bearers
undergoes surgical revision, mostly for aseptic loosening
or PPI [42]. However, increasing numbers of revisions for
unclear symptoms or following inconclusive work-up pro-
cedures are being recorded annually [43, 44]. It is in the
context of these cases, that the present study is intending
to raise awareness for rare problem elicitors, such as aller-
gic or adverse reactions. As a matter of fact, only about
10% of orthopaedic surgeons report that they regularly
screen their patients for relevant hypersensitivities [45].
Table 3 Patient and implant characteristics including date of implantation and implant type, allergy history, symptoms, patch test
results, timing of allergy work-up and revision surgery, and change in KOOS scores (CoCroMo incl. Ni+, cobalt-chromium-
molybdenum alloy includes up to 1% nickel; AA, allergic asthma; AR, allergic rhinitis; FA, family history of atopy; AE, atopic eczema;
ARM, self-reported intolerance reactions to metallic objects; JP, joint pain; Sw, swelling; Er, localized erythema; Ec, localized eczema;



















none JP, Sw, JE, LA Genta 28 33 56 + 62.1




FA JP, LA Genta 19 22 54 + 18.9




FA JP, Sw, JE, LA Genta 11 15 52 + 07.6




FA JP, Sw, JE, LA Genta 13 17 45 + 68.9




AR, ARM JP, Sw, Er, Ec, LA Genta 4 no rev 45 + 11.3




AR, AA, AE Sw, JE Genta 19 no rev 43 − 04.6




none JP, Sw, LA Genta 14 18 37 + 33.4




none JP, Sw Genta 13 17 37 + 19.2




none Sw, LA Genta 16 no rev 35 + 01.5




AR, AA, AE, FA JP, Sw, LA Genta 35 38 33 − 14.4




none JP, Ec, JE, LA Genta, BPO 13 no rev 31 + 03.8




AR, ARM, FA JP, Sw, LA Ni, Genta 53 no rev 26 + 56.0




ARM JP, Ec, JE, LA Genta 6 no rev 26 + 28.8




FA JP, Sw, JE, LA Genta 19 27 25 + 03.7




ARM JP, Sw, JE, LA Ni, Genta 12 15 23 + 16.7
†Interval between primary implantation of joint replacement (JR) and allergy work-up (WU) in months
§Interval between primary implantation of joint replacement (JR) and revision surgery (RS) in months
£Interval between allergy work-up (WU) and follow-up (FU) in months
‡Individual KOOS index difference (absolute change)
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Clinical observations of BC allergy as potential elicitor
of arthroplasty failure have been reported as early as the
1970s [46, 47]: the allergens in question were acrylates,
namely, methylmethacrylate (MMA) and additives, like
BPO or DMPT. In 1996, Haddad et al. observed a high
prevalence of positive patch test reactions to DMPT in a
series of patients with early onset of aseptic implant
loosening [48]. The importance of adequate preoperative
history taking and patch testing—e.g., in patients with
contact dermatitis to acrylic finger nails—has been
discussed in a 2002 case report by Kaplan et al. [49] and
a recent report by Alamri and colleagues [50]. Despite
several reports focusing on BPO as an allergenic compo-
nent in poorly tolerated cemented TJRs, its role in
implant allergy remains controversial [51, 52]; BPO,
despite its strong irritant potential, only acts as a weak
allergen, resulting in false positive patch test reactions
[53, 54]. Furthermore, its ongoing release from bone
cement is questionable. This doubt is supported by the
fact that BPO is metabolized rapidly as part of its
function as redox initiator in the polymerization process
[8, 9]. It is therefore doubtful whether BPO remnants
are still present at the site of cementation after the
curing process is complete. Nonetheless, Bircher et al.
showed that removal of BC and change to uncemented
endoprostheses resulted in considerable symptomatic
improvements in 4 out of 5 BPO allergic patients with
TJR [34]. Similarly, Vega et al. [36] and Kenan et al. [35]
observed satisfactory long-term courses of uncemented
revision arthroplasties in patients allergic to MMA, a BC
component known to remain considerably longer at the
site of implantation in cases of incomplete polymerization.
In our patients, however, the main reason for revision
surgery was contact allergy to gentamicin sulfate, as con-
firmed by positive patch testing. Aminoglycoside antibi-
otics are well studied contact allergens [55], known to be
responsible for contact dermatitis to topical drugs in
particular, with gentamicin sulfate leading the way [56].
In line with this, a longitudinal study of 620 Finnish
patients with suspected contact allergy revealed a 4.6%
prevalence of positive patch test reactions to gentamicin
[57]. However, our 15 patients did not report any in-
tolerance or dermatitis to topical (potentially gentamicin
containing) drugs. On the other hand, due to lifetime
cumulative exposure, contact allergy to topical drugs
becomes more prevalent with advancing age, which
coincides with an increased demand for TJR [58]. How-
ever, reports of gentamicin allergy in cemented arthro-
plasty are scarce, apart from our preceding study [32].
Haeberle et al. presented a patient with a potentially
gentamicin-related systemic contact dermatitis upon
cemented TKR [59]. Christiansen et al. even reported a
case of anaphylaxis with cardiac arrest after intravenous
administration of gentamicin during a routine laparo-
scopic procedure, with thorough work-up revealing a
previous cemented TKR as the suspected cause of
sensitization [60]. Albeit devastating, the patient’s symp-
toms were of systemic nature and did not affect the TJR
itself.
The abovementioned acute systemic reactions are
starkly contrasted by the late onset and prolonged
Fig. 5 Correlation of KOOS scores upon first visit and the incidence
of revision surgery. Baseline KOOS (Knee Injury and Osteoarthritis
Outcome Score) indices of the 15 patients at first visit (i.e., time of
allergy diagnostics). Scatterplot displaying the correlation of low
KOOS indices (i.e., high symptom severity) and the decision to
proceed with revision surgery in 9 patients (“revision”)
Fig. 6 Revision surgery provides significant symptom relief in
allergic patients. Split-plot repeated measures factorial ANOVA
visualizing the improvement of KOOS (Knee Injury and Osteoarthritis
Outcome Score) indices in the 6 patients without revision
(“untreated”) and the 9 patients with revision (“treated”).
Improvement was significant only in the “treated” group. Of note,
patient 10 of the revision group displayed a score deterioration of
14.4 points (dark red). In this case, severe intra-articular arthrofibrosis
was confirmed as the symptom elicitor by the treating orthopaedic
surgeon. n.s., not statistically significant; *p < 0.05, primary, at first
visit (i.e., time of allergy diagnostics)
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persistence of localized symptoms in our cohort of
contact allergic patients. Allergic reactions in the sense
of delayed type hypersensitivity may persist for a longer
period of time even when continuous allergen exposure
is low or has already stopped. This fact was well illus-
trated in an exemplary case by Wittman et al. [61], who
described a gentamicin allergic patient with persistent
and otherwise unexplained local symptoms following
uncemented TKR. Meticulous history taking revealed a
single intra-articular injection of gentamicin performed
during an outpatient check-up as the elicitor of months-
long local pain and swelling in this case. Of note, our
results also demonstrate that in patients with less
pronounced symptoms, complaints decreased as well,
but they did so to a lesser degree. This might be
explained by the gradually decreasing gentamicin release
from BC over time.
Finally, our present study does have some weaknesses.
First, and most importantly, our cohort only comprised
a relatively small number of individuals, which compli-
cates the generalizability of the conclusions drawn.
Nevertheless, taking the large sample size of the primary
study population into account, the numbers are suffi-
ciently high to emphasize the importance of gentamicin
contact allergy in complicated TJR. Secondly, our study
is limited by its retrospective nature and involvement of
several treating orthopaedic surgeons and their presum-
ably slightly different treatment protocols, particularly
with regard to their preference of considering positive
patch test reactions as an indication for revision surgery.
Third, we did not include serological investigations,
histopathological sampling, or molecular methods to aid
in the diagnosis of hypersensitivity. Thus, we were not
able to compare the aforementioned diagnostic tech-
niques in the context of suspected allergy to bone ce-
ment components. However, patch testing still remains
the gold standard in detecting symptomatic contact
allergy and was therefore deemed sufficient as the sole
diagnostic criterion. Fourth, we did not analyze further
patient characteristics, such as the pre-arthroplasty con-
dition of their knees, potentially confounding comorbidi-
ties, or socioeconomic status, all of which might have
contributed to their unsatisfactory primary TKA out-
comes. Fifth, only 15 of all 25 patients diagnosed with
gentamicin contact allergy were available for a follow-up
visit, which might represent an inherent selection bias:
namely, patients diagnosed with gentamicin contact al-
lergy who did not profit from revision surgery might
have refused to participate in our follow-up study, as
opposed to those who did. Ultimately, we only used the
KOOS to evaluate the course of symptoms and assess
post-revision outcomes. Despite good evidence for reli-
ability, validity, and responsiveness, the KOOS remains a
solely self-reported score, omitting further objectifiable
clinical and diagnostic criteria (such as range of motion
or radiographic measurements) [62, 63]. One could
therefore argue that an alternative scoring system, such
as the New Knee Society Score, which contains a section
of objective findings, would be better suited to deter-
mine the potential benefit of TKA revisions [64, 65].
However, despite these acknowledged weaknesses, our
study provides encouraging evidence for the clinical rele-
vance of an allergy work-up in cases of complicated TJR.
These limitations do not weaken the strong correlation
between gentamicin contact allergy and symptom im-
provement following revision surgery.
Conclusion
With an ever-aging population, the demand of TJR is on
the rise. At large, arthroplasty failure results in both a
far-reaching physical and considerable financial burden
on patients, physicians, and taxpayers. Consequently,
trying to elucidate the mechanisms of premature implant
failure remains a crucial multi-disciplinary challenge. In
this context, particularly when symptoms persist despite
an inconclusive work-up, rare conditions like implant al-
lergy or adverse reactions should be considered as diag-
noses of exclusion. In conclusion, our findings indicate
that gentamicin allergy could represent a relevant prob-
lem elicitor in cemented arthroplasty. To our knowledge,
this is the first study assessing the clinical relevance of
gentamicin contact allergy in a single-center cohort of
symptomatic patients with aseptic cemented TKR. To
conclude, larger cohort studies, preferably multicenter in
nature, as well as investigations of other joints, need to
be performed to further corroborate our findings regard-
ing the clinical relevance of gentamicin allergy in TKA.
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